Previous 10 | Next 10 |
Corbus Pharmaceuticals press release ( NASDAQ: CRBP ): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures. ...
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission...
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference PR Newswire CRB-601 is a highly potent and selective anti -αvβ8 integrin monoclonal antibody designed to block t...
Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q1 GAAP EPS of -$0.08 beats by $0.01. As of March 31, 2022, the company has $86.8 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures. Promisi...
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission ...
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire NORWOOD, Mass. , April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Comp...
Penny stocks are a great way to make money in the stock market. They’re also an incredible way to take advantage of speculation. Whether it’s weeks leading up to a potential FDA decision, a period of global unrest (like we’ve seen recently), or pending government decisi...
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference - Fireside chat with live video webcast on Thursday, March 17th at 8:00 AM ET PR Newswire NORWOOD, Mass. , March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdin...
Corbus Pharmaceuticals press release (NASDAQ:CRBP): FY GAAP EPS of -$0.37 beats by $0.03. Revenue of $0.88M (-77.8% Y/Y) beats by $0.04M. As of December 31, 2021, the Company has $98.3 million of cash and investments on hand Shares +3.15% PM. For further details see: Corbus P...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates - Company is advancing its integrin program and on schedule for initiating clinical studies in 2023 - Expanding immuno-oncology pipeline through strategic transac...
News, Short Squeeze, Breakout and More Instantly...
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announ...
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study bein...
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 42.2% to $0.0512 on volume of 330,264,926 shares PROSHARES TRUST (SQQQ) rose 6.4% to $12.84 on volume of 220,628,201 shares AGBA Group Holding Limited (AGBA) rose 21.4% to $1.25 on volume of 128,109,386 shar...